Abstract
Topically administered bimatoprost 0.03%/timolol 0.5% ophthalmic solution (bimatoprost/timolol: Ganfort) comprises the synthetic prostamide bimatoprost (structurally related to prostaglandin F2 alpha) and the beta-adrenergic receptor antagonist timolol. Bimatoprost/timolol (one drop administered in the affected eye[s] once daily in the morning or evening) is an effective and well tolerated fixed combination for lowering intra-ocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension (OHT), including individuals uncontrolled on monotherapy with a beta-adrenergic receptor antagonist or prostaglandin analogue/prostamide.
MeSH terms
-
Amides / administration & dosage*
-
Amides / adverse effects
-
Amides / pharmacokinetics
-
Antihypertensive Agents / administration & dosage*
-
Antihypertensive Agents / adverse effects
-
Antihypertensive Agents / pharmacokinetics
-
Bimatoprost
-
Clinical Trials as Topic
-
Cloprostenol / administration & dosage
-
Cloprostenol / adverse effects
-
Cloprostenol / analogs & derivatives*
-
Cloprostenol / pharmacokinetics
-
Cost-Benefit Analysis
-
Drug Combinations
-
Glaucoma / drug therapy*
-
Humans
-
Latanoprost
-
Ocular Hypertension / drug therapy*
-
Prostaglandins F, Synthetic / administration & dosage
-
Timolol / administration & dosage*
-
Timolol / adverse effects
-
Timolol / pharmacokinetics
Substances
-
Amides
-
Antihypertensive Agents
-
Drug Combinations
-
Prostaglandins F, Synthetic
-
Cloprostenol
-
Latanoprost
-
Timolol
-
Bimatoprost